<DOC>
	<DOCNO>NCT00402116</DOCNO>
	<brief_summary>There 2 phase study . Patients either enrol first phase second phase , depend upon enroll study . The first phase study do evaluate safety enzastaurin patient . This do gradually increase dose drug small group patient watch closely side effect . In second phase study , dose determine safe use temozolomide follow radiation therapy see combination help patient brain tumor live long .</brief_summary>
	<brief_title>Phase 1/2 Study Newly Diagnosed Glioblastoma Multiforme ( GBM ) Gliosarcoma ( GS ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>Patients must histologically confirm diagnosis intracranial glioblastoma multiforme ( GBM ) gliosarcoma ( GS ) . Biopsy resection must perform 5 week prior treatment . An MRI CT scan must obtain within 14 day prior treatment . Patients must receive prior drug therapy brain tumor . Patients must adequate organ function demonstrate lab test within 14 day prior treatment . Patients exclude unable swallow tablet . Patients exclude unable discontinue use enzyme induce antiepileptic drug agent le 2 week prior treatment ( i.e . phenytoin ( Dilantin ) , carbamazepine , etc. ) . Patients exclude active infection . Patients exclude significant medical illness , investigator 's opinion , adequately controlled appropriate therapy would compromise patient 's ability tolerate therapy . Patients exclude concurrent therapy anticoagulant . If patient require anticoagulant therapy start treatment , patient may remain study monitor carefully .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>